Sutro Biopharma (STRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $163.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sutro Biopharma (STRO) Stock Forecast
Analysts expect Sutro Biopharma (STRO) to earn -$7.48 per share in the fiscal year ending Dec 31, 2026, on revenue of $52.63M. Of 14 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 21.4% |
| Buy | 10 | 71.4% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 7.1% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 40.7%.
- Fiscal year ending Dec 31, 2026
- -$7.48
- EPS consensus, revenue $52.63M
- Fiscal year ending Dec 31, 2027
- -$6.11
- EPS consensus, revenue $31.23M
- Next report
- Mar 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$7.48 | -$8.57 to -$6.39 | 2 | $52.63M | $29.36M to $124.40M | 12 |
| Dec 31, 2027 | -$6.11 | -$9.32 to -$4.31 | 3 | $31.23M | N/A | 12 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.72 | -$2.70 to -$0.95 | 16 | $11.62M | $2.45M to $21.96M | 14 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$8.47.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$7.48 | -$7.77 | -$7.77 | -$7.77 | -$8.47 | N/A |
| Fiscal year ending Dec 31, 2027 | -$6.11 | -$6.21 | -$6.21 | -$6.21 | -$6.39 | N/A |
Frequently Asked Questions About STRO
What is the STRO stock forecast?
Consensus analyst estimates put Sutro Biopharma's EPS at -$7.48 for the fiscal year ending Dec 31, 2026, on revenue of $52.63M. The consensus rating from 14 analysts is Buy.
How do analysts rate STRO stock?
Of 14 analysts covering Sutro Biopharma, 3 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from STRO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$7.48, with estimates from -$8.57 to -$6.39 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$6.11, with estimates from -$9.32 to -$4.31 from 3 analysts.
What revenue do analysts expect from Sutro Biopharma next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $52.63M, with estimates from $29.36M to $124.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $31.23M.
How many analysts cover STRO?
14 analysts rate Sutro Biopharma stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
STRO pages: Overview, Earnings, Forecast, Financials, Competitors